Skip to main content
x

Recent articles

NextCure joins the B7-H4 brigade

Meanwhile, Olema’s KAT6 inhibitor will take on rival projects from Pfizer and Menarini.

ASCO-GI – a second colorectal win for Bristol's combo

Opdivo and Yervoy succeed again, but the US path remains unclear.

ASCO-GI – ALX resurrects evorpacept

The company reveals fresh biopsy status as a primary endpoint, and declares Aspen-06 a win.

ASCO-GI – Exelixis’s son of Cabometyx disappoints

The company might need something better to replace its ageing blockbuster.

Innate challenges Pfizer in Nectin-4

While Cogent joins the FGFR party.

ASCO-GI – no masking Xilio's setback

Poor efficacy clouds prospects for the company's "improved" Yervoy.